Skip to main content
Concord Biotech Limited logo

Concord Biotech Limited — Investor Relations & Filings

Ticker · CONCORDBIO ISIN · INE338H01029 LEI · 335800FBIZZTLAXLXZ73 BSE.NS Manufacturing
Open in API
Filings indexed 227 across all filing types
Latest filing 2023-09-30 Regulatory Filings
Country IN India
Listing BSE.NS CONCORDBIO

About Concord Biotech Limited

https://concordbiotech.com/

Concord Biotech Limited is a research and development-driven company specializing in the production of fermentation-based Active Pharmaceutical Ingredients (APIs) and finished formulations. The organization focuses on niche therapeutic areas, including immunosuppressants, oncology, anti-fungals, and anti-infectives. It maintains a significant global presence, supplying products to regulated markets such as the United States, Europe, and Japan. Concord Biotech operates large-scale fermentation facilities and is recognized for its expertise in complex manufacturing processes. Its operations are vertically integrated, covering the entire value chain from strain development and fermentation to downstream processing and formulation. The company adheres to international quality standards, holding certifications from major regulatory bodies like the USFDA and EUGMP, ensuring the delivery of high-quality pharmaceutical solutions to its global clientele.

Recent filings

Filing Released Lang Actions
Resignation of Independent director
Regulatory Filings
2023-09-30 English
Resignation
Board/Management Information Classification · 100% confidence The document is a formal announcement regarding the resignation of an Independent Director, Mr. Utpal Hemendra Sheth, from Concord Biotech Limited. It references compliance with Regulation 30 of the Securities and Exchange Board of India (Listing Obligations and Disclosure Requirements) Regulations, 2015, which pertains to disclosure of events or information by listed entities. The content includes details about the resignation, the effective date, and a resignation letter from the director. There are no financial statements, earnings data, or report publications included. The document is clearly an announcement of a change in the company's board of directors, fitting the category of Board/Management Information (MANG). The document length and detail confirm it is not a brief notice or a report publication announcement but a substantive disclosure about management change.
2023-09-30 English
Trading Window
Regulatory Filings Classification · 95% confidence The document is a formal letter from Concord Biotech Limited addressed to stock exchanges notifying the closure of the trading window in compliance with SEBI regulations ahead of the announcement of quarterly and half-year financial results. It does not contain any financial data or results itself, nor does it present a report. The document is short (2294 characters) and serves as an announcement related to insider trading restrictions before financial results are declared. Therefore, it is not an Interim Report or Earnings Release but rather a Regulatory Filing notifying the trading window closure period.
2023-09-22 English
Analysts/Institutional Investor Meet/Con. Call Updates
Call Transcript Classification · 100% confidence The document is a detailed transcript of the Q1 FY24 earnings conference call for Concord Biotech Limited held on September 7, 2023. It includes management commentary, financial highlights, market overview, and a Q&A session. The text explicitly mentions it is an "Earnings Conference Call" transcript and contains detailed discussion of quarterly financial and operational performance. It is not a brief announcement or a report publication notice, but a full transcript of the earnings call. Therefore, the document fits the category of a Call Transcript (CT).
2023-09-13 English
Copy of Newspaper Publication
Regulatory Filings
2023-09-08 English
Analysts/Institutional Investor Meet/Con. Call Updates
Regulatory Filings Classification · 95% confidence The document is a letter addressed to stock exchanges regarding an earnings call recording for the quarter ended June 30, 2023. It references Regulation 30 of SEBI (Listing Obligation and Disclosure Requirement) Regulation, 2015, and informs about the hosting of the audio recording of the earnings call on the company's website. The document does not contain actual financial data or detailed financial results but is an announcement about the earnings call recording availability. The document length is 2300 characters, which is short and consistent with an announcement rather than a full report or transcript. Therefore, it is best classified as a Regulatory Filing (RNS) because it is a regulatory announcement about the earnings call recording, not the earnings release itself or the call transcript.
2023-09-07 English

Browse filings by year

4 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.